In-Med Prognostics, an artificial intelligence (AI) startup with expertise in multi-modal data and image processing, has raised $2.13 million led by Exxora with participation from prominent angels. The funds will be used to stabilise and expand the product portfolio and tap global markets.

In-Med Prognostics leverages deep learning algorithms and machine learning to provide time saving accurate neuro analysis which aids in assessment and early detection of neurological disorders such as Dementia, Alzheimer’s and Parkinson’s at affordable prices. 

Their ‘Neuroshield’ solution provides a self-explanatory volumetric report within an analysis time of 20 minutes. The startup offers AI powered image processing proprietary  software for neurologist decision support and radiologist workflow enhancement.

The company is the first in the world to provide ethnicity specific neuro assessment reports and multi-modal data processing capability to develop integrated digital biomarkers.

In-Med India was founded in 2018 and had announced a Rs 50 lakh Grant from BIRAC in 2019. In-Med Inc, the US holding company was formed in 2021. The company has since secured global IP and a new CT Tool has been deployed.  

In India, In-Med Prognostics is already working with Aarthi Scans, Scansworld, Gujarat Scans, Nanavati, Cauvery hospitals. The company is expanding to Africa and is targeting a global multi billion diagnostic and wellness market.